Published online Mar 31, 2010.
https://doi.org/10.4048/jbc.2010.13.1.104
Cost-Effectiveness of Genexol-PM for Treating Metastatic Breast Cancer
Abstract
Purpose
The aim of this study was to determine the incremental effectiveness (the differences in progression-free survival between treatments), the incremental cost and the incremental cost-effectiveness of Genexol-PM compared to Paclitaxel when these drugs were used as treatment for patients with metastatic breast cancer.
Methods
In the absence of any comparative direct evidence of the relative efficacy of Paclitaxel and Genexol-PM in this setting, a meta-analysis was conducted to determine the effects of the Paclitaxel on the health outcome. The decision tree model was constructed to evaluate the two treatment regimens. All the costs are in 2008 Korean Won (KW) and they were evaluated according to the 3rd party payer perspective, and the direct nonmedical and indirect costs were excluded.
Results
When compared with Paclitaxel, Genexol-PM was shown to increase the response rate and the time to progression for patients with metastatic breast cancer. Although the overall treatment costs of Genexol-PM were slightly higher than those of Paclitaxel, Genexol-PM was associated with a delayed time to progression of 4.78 months per patient. The incremental cost effectiveness ratio for Genexol-PM versus Paclitaxel was KW 2,295,228 per year gained, which is far below the per capita GDP or the threshold of the willingness-to-pay in Korea.
Conclusion
Compared with Paclitaxel, Genexol-PM for treating metastatic breast cancer is within the acceptable range of the cost-effectiveness ratio for medical intervention.
Figure 1
Decision tree.
Figure 2
M=Million Korean Won.
Tornado diagram (cost-effectiveness threshold: 20,000,000 Korean Won).
Table 1
Studies included in the Paclitaxel treatment meta-analysis
Table 2
Estimated drug costs
Table 3
Cost-effectiveness analysis
Table 4
Base-case estimates and ranges used in sensitivity analysis
References
-
Kim SW, Han W, Jeong J, Park HK, Noh WC, Lee ES, et al. The policy proposal for effective prevention and management of breast cancer. J Breast Cancer 2006;9:270–292.
-
-
SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. 2007 [accessed September 24th, 2009].http://seer.cancer.gov/csr/1975_
2004.
-
-
2005 Annual report of the central cancer registry in Korea. Ministry for Health Welfare and Family Affairs, Cancer Registry Center; [accessed September 24th, 2009].
-
-
Park WC, You YK, Choi SH, Suh YJ, Oh SC, Cho WI, et al. Therapeutic effects of paclitaxel (Taxol) in metastatic breast cancer. J Korean Surg Soc 1999;56:509–514.
-
-
Limwattananon S, Limwattananon C, Maoleekulpairoj S, Soparatanapaisal N. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. J Med Assoc Thai 2006;89:690–698.
-
-
Reichman BS, Seidman AD, Crown JPA, Heelon R, Hakes TB, Lebwohl DE, et al. Paclitaxel and recombinant human granulocyte colonystimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943–1951.
-
-
Davidson NG. Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer. Semin Oncol 1995;22:2–6.
-
-
Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995;22:33–39.
-
-
Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575–2581.
-
-
Davidson NG, Chick JB, Perren TJ, Campbell N, Thompson JM, Chan YT. A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. Clin Oncol 1996;8:358–362.
-
-
Fountzilas G, Athanassiades A, Giannakakis T, Bafaloukos D, Karakousis K, Dombros N, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996;32:47–51.
-
-
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858–1867.
-
-
Michael M, Bishop JF, Levi JA, Bell DR, Zalcberg JR, Friedlander ML, et al. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Aust 1997;166:520–523.
-
-
Bishop J, Dewar J, Toner G, Smith J, Tattersall M, Olver I, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355–2364.
-
-
Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999;17:3038–3047.
-
-
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000;18:724–733.
-
-
Liu F, Jiang ZF, Song ST, Liu XQ, Wang T, Yan M, et al. Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer. Zhonghua Zhong Liu Za Zhi 2005;27:56–58.
-